

## Index

### a

- ABT-667, chemical structure 367  
 ABT-675 366–367  
 – inhibitor potency and oral bioavailability 367  
 acquired immunodeficiency syndrome (AIDS)  
 – HIV as causative agent 51–52  
 – manageable chronic disease 73  
 – RNAi gene therapy 338–339  
 acute respiratory syncytial virus infection 337  
 ACV *see* acyclovir  
 acyclic nucleoside phosphonates (ANPs) 231  
 – antiviral activity spectrum 96  
 – antiviral drugs 95  
 – human cytomegalovirus DNA polymerase inhibitor 244  
 – main classes 95–99  
 acyclic nucleoside phosphonates, oral prodrugs 189–198  
 acyclovir (ACV) 229  
 – mechanism of action 232  
 adamantanamine-based M2 ion channel protein inhibitors, influenza treatment 352–353  
 adefovir *see also* acyclic nucleoside phosphonates  
 – acyclic nucleoside phosphonates 95–97  
 – hepatitis B virus and HIV 11, 97–99  
 adefovir derivative, as prodrug of nucleoside phosphonates 197–198  
 adefovir dipivoxil, clinical application of nucleoside phosphonate 112–113  
 adenovirus  
 – acyclic nucleoside phosphonates 95–96, 191, 193, 195  
 – antiviral drugs 13  
 AIDS *see* acquired immunodeficiency syndrome  
 alkoxyalkyl ester of nucleoside 5'-monophosphates, prodrugs 185–189  
 alkoxyalkyl ester prodrugs  
 – of nucleoside phosphates 185–189  
 – of nucleoside phosphonates 181–185  
 – of phosphonoformate 185  
 alkoxyalkyl esters  
 – of (*S*)-HPMPA 191–196  
 – of tenofovir (HDP-(*R*)-PMPA) 196–197  
 alkylglycerol prodrugs, of phosphonoformate 185  
 alphaherpesviruses *see* herpes simplex virus; varicella zoster virus  
 amantadine, influenza treatment 352–353  
 ambiguous base pairing, 5-aza-5,6-dihydro-2'-deoxycytidine 292–293  
 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (S2242), human cytomegalovirus DNA polymerase inhibitor 238–239  
 amphipathic DNA polymers, human cytomegalovirus entry inhibitor 237  
 amprenavir  
 – brand name and manufacturer 5  
 – chemical structure 76  
 – comparison to darunavir 85–86  
 – discovery 3, 77–78  
 – HIV protease inhibitor 80  
 – *in vitro* resistance selection experiment 83–85  
 amprenavir monophosphate (fosamprenavir), amprenavir replacement 78  
 ANPs *see* acyclic nucleoside phosphonates  
 antagonists  
 – CCR5 38–40  
 – CXCR4 40–41  
 anti-cytomegalovirus agents *see also* anti-human cytomegalovirus compounds  
 – maribavir 209–221

- overview 209–210
  - anti-HIV drugs
    - lethal mutagenesis 283–284
    - resistance 283, 295–296
  - anti-HIV evaluation 377
  - anti-human cytomegalovirus
    - compounds 227–265
    - novel viral targets 235–260
  - anti-human cytomegalovirus drugs
    - classes 229–231
    - clinical use 229–234
    - need for new drugs 234–235
    - prophylaxis and treatment 229
    - resistance 233–234
    - toxicity 231–233
  - anti-influenza agents, neuraminidase inhibitors 351–370
  - anti-influenza drugs 352
  - antiretroviral therapy, HIV 29, 52
    - see also* highly active antiretroviral therapy
  - antisense nucleotide, formivirsen 230
  - antiviral activities
    - benzimidazoles 1
    - darunavir 81, 85–86
    - iododeoxyuridine 1
    - ribavirin 2 (*see also* ribavirin)
    - thiosemicarbazones 1
  - antiviral activity spectrum, of acyclic nucleoside phosphonates 96
  - antiviral compounds, oral activity 182–184
  - antiviral drug discoveries, milestones 3
  - antiviral drug era, overview and key events 1–4
  - antiviral drugs
    - against DNA viruses 13
    - against hepatitis B virus 12
    - against herpesviruses 4–8
    - against retroviruses (HIV) 8–12
    - alternatives 19
    - brand names 5–6
    - first 1 (*see also* iododeoxyuridine)
    - for hepatitis C virus 15–17
    - for influenza A virus infections 14–15
    - for poxviruses 17–18
    - manufacturers 5–6
    - milestones of discoveries 3
    - resistance to (*see* drug-resistant mutations)
  - antiviral RNAi, virus silencing 329–339
  - artemisinin 258
  - artesunate, human cytomegalovirus inhibitors 258, 260
  - 2-aryl-2-hydroxyethylamine substituted
    - 4-oxo-4,7-dihydrothieno[2,3-b]pyridines, human cytomegalovirus DNA polymerase inhibitor 240
  - arylsulfone derivatives, human cytomegalovirus inhibitors 257–259
  - 5-azacytidine (5AZC)
    - mechanism of action 291
    - mutagenic HIV pharmaceutical 291–292
  - 5-aza-5,6-dihydro-2'-deoxycytidine (KP-1212)
    - development 292–294
    - mechanism of action 292
    - mitochondrial toxicity 293
  - AZT *see also* zidovudine
    - brand name and manufacturer 5
    - chemical structure 9
    - enhancement of prodrugs 185
- b**
- BAY 38-4766 *see* phenylenediamine sulphonamides
  - BCX-1812 *see* peramivir
  - BDCRB *see* 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole
  - benzimidavir, benzimidazole ribosides *see* maribavir
  - benzimidazole compounds, anti-cytomegalovirus activity 210
  - benzimidazole ribonucleoside, maribavir 209–221
  - benzimidazole ribosides, human cytomegalovirus replication inhibitors 250–252
  - benzimidazoles, antiviral activity 1
  - 4'-benzoyl-ureido-TSAO derivatives, human cytomegalovirus inhibitors 258–259
  - 1-benzylloxycarbonylazetidines 250
  - berberine chloride, human cytomegalovirus inhibitors 257–259
  - bioavailability, oral 107–111
  - bioisosteres
    - cyclic nucleoside phosphonates 99–101
    - nucleoside phosphonates 92
  - biological weapon, smallpox (variola virus) 17, 189
  - boceprevir 320–321
    - binding to NS3 protease variants 316–318
  - brand names, antiviral drugs 5–6
  - (2-bromo-5,6-dichloro-1-(β-D-pyranosyl)benzimidazole) (GW275175X), cytomegalovirus inhibitor 210

- 2-bromo-5,6-dichloro-1- $\beta$ -D-ribofuranosyl  
benzimidazole (BDCRB), human  
cytomegalovirus replication  
inhibitors 210, 252
- C**
- caliciviridae, targeted by RNAi 333
- carbocyclic nucleoside phosphonates, cyclic  
nucleoside phosphonates 105
- CCR5 antagonists
- HIV entry 38–40
  - resistance to 39–40
- CDK *see* cyclin-dependent kinase
- CDV *see* cidofovir
- chain terminators *see also* delayed chain  
terminators
- blocking of viral replication 94
  - 2-C-methylsubstituted ribonucleosides  
4, 15
  - 2',3'-dideoxynucleoside analogues 9
  - entecavir 12
  - obligatory and delayed 94
  - RNA 105
- chemokine receptors agonist, human  
cytomegalovirus-encoded receptors  
256–258
- chemotherapy era, antiviral 1
- 2-chloro-3-pyridin-3-yl-5,6,7,8-  
tetrahydroindolizine-1-carboxamide  
(CMV423), human cytomegalovirus  
inhibitors 258
- 8-chloro-TIBO (R86183) 378
- cHPMP-5-azaC *see* cyclo-1-(3-hydroxy-2-  
phosphonylmethoxypropyl)-5-aza-  
cytosine (cHPMP-5-azaC)
- chronic hepatitis C 307
- cidofovir (CDV) 229–230
- alkoxyalkyl ester derivatives 244
  - anti-cytomegalovirus agent 209
  - broad-spectrum activity 231
  - clinical application of nucleoside  
phosphonate 112
  - Epstein–Barr virus 190
  - human cytomegalovirus retinitis 231
  - mechanism of action 231–232
  - molluscivirus 112
  - other double-stranded DNA viruses  
190–191
  - papillomavirus 112
  - poxviruses 189–190
  - toxicity 233
- ciluprevir, hepatitis C virus 4
- clinical applications, nucleoside  
phosphonates 111–115
- clinical development
- cyclophilin inhibitors 148, 149
  - darunavir 86–87
- clinical results in hepatitis C virus,  
cyclophilins 159–167
- 2-C-methylsubstituted ribonucleosides, chain  
terminators 4, 15
- CMV *see* cytomegalovirus
- CMV423 *see* 2-chloro-3-pyridin-3-yl-5,6,7,8-  
tetrahydroindolizine-1-carboxamide
- CNPs *see* cyclic nucleoside phosphonates
- combination drug strategy, prevention of drug  
resistance 19–20
- congenital cytomegalovirus *see* human  
cytomegalovirus
- congenital human cytomegalovirus  
infection 228–229
- coreceptors, virus tropism and infectivity  
33
- coronaviridae, targeted by RNAi 333
- covalent linear hepatitis C virus protease  
inhibitors
- chemical structures 311
  - enzyme-inhibitor interaction kinetics 311
  - log octanol/water partition coefficient 311
  - mechanism of action 310
  - molecular weights 311
  - pattern of resistance 316–318
  - polar surface area 311
- covalent linear protease inhibitors,  
resistance 316–318
- cowpox
- acyclic nucleoside phosphonates 190–194
  - antiviral drugs 17–18
- COX-2 *see* cyclooxygenase-2
- CS-8958 *see* laninamivir
- CsA *see* cyclosporin A
- CXCR4 antagonists, HIV entry 40–41
- cyclic nucleoside phosphonates (CNPs)
- antiviral drugs 99
  - examples of targeting viral RNA  
polymerases 104–107
  - main classes 100–104
  - oral prodrugs 189–198
- cyclin-dependent kinase (CDK) 261
- cyclin-dependent kinases inhibitors, human  
cytomegalovirus 261–262
- cyclo-1-(3-hydroxy-2-  
phosphonylmethoxypropyl)-5-aza-cytosine  
(cHPMP-5-azaC), human cytomegalovirus  
DNA polymerase inhibitor 241, 245
- cyclooxygenase-2 (COX-2) 263
- cyclooxygenase-2 inhibitors, human  
cytomegalovirus 262–263

- cyclopentane and cyclopentene core
    - phosphonates, cyclic nucleoside phosphonates 103–104
  - cyclophilin inhibitors
    - against HIV-1 151–152
    - currently in clinical development 148, 149
    - generation 168–169
    - new noncyclosporine species 168
  - cyclophilins *see also* cyclosporin A
    - activity against other viruses 167
    - clinical results in hepatitis C virus 159–167
    - hepatitis C virus 155–159
    - HIV treatment 149–155
    - overview 148
  - cyclopropavir, human cytomegalovirus DNA polymerase inhibitor 239–242
  - cyclosporin A, immunosuppression 147
  - cyps *see* cyclophilins
  - cytomegalovirus (CMV) *see also* human cytomegalovirus
    - 2-bromo-5,6-dichloro-1-( $\beta$ -D-ribofuranosyl) benzimidazole (BDCRB) 210
    - chemical classes of inhibitors 210–211
    - diseases 210, 215–220
    - drugs 209–210
    - inhibition of DNA maturation process and encapsidation 210
    - inhibition of DNA polymerase 210
    - inhibition of protein kinase pUL97 211
    - (2,5,6-trichloro-1-( $\beta$ -D-ribofuranosyl) benzimidazole (TCRB) 210
    - unmet challenges 209–210
  - cytomegalovirus retinitis *see also* human cytomegalovirus retinitis
    - AIDS patients 227
    - intraocular delivery 198–201
    - maribavir treatment 214
    - under highly active antiretroviral therapy (HAART) 217
  - Cytovene® *see* ganciclovir
- d**
- DAA drugs *see* direct acting antiviral drugs
  - DANA *see* 2-deoxy-2,3-didehydro-N-acetylneuraminic acid
  - dapivirine (R147681, TMC120) 380
  - DAPY *see* diarylpyrimidine
  - darunavir
    - antiviral activities 81, 85–86
    - brand name and manufacturer 5
    - chemical structure 10, 76
    - clinical development 86–87
    - enfuvirtide 41
    - hydroxyethylene scaffold 11
    - ribbon structure of HIV-1 protease 79
    - synthesis scheme 84
  - DATA *see* diarylthiazine
  - delayed chain terminators *see also* chain terminators
    - blocking of viral replication 94
  - dendrimers, human cytomegalovirus entry inhibitor 235–237
  - dengue virus, antiviral drugs 19
  - 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA)
    - carbocyclic analogues 360–361
    - carbocyclic scaffold 359
    - inhibitor activity 356
  - deoxycytidine analogues
    - 5-aza-5,6-dihydro-2'-deoxycytidine 292
    - 5-Hydroxy-2'-deoxycytidine 290–291
  - deoxyguanosine analogue, ganciclovir 229
  - deoxyribose nucleosides, lethal mutagens 287
  - diarylpyrimidine (DAPY)
    - analogues 381
    - chemical structure 380
  - diarylthiazine (DATA)
    - analogues 381
    - chemical structure 380
  - 5,6-dichloro-1- $\beta$ -D-ribofuranosyl benzimidazole (DRB), influenza virus multiplication 1
  - dideoxyfuranopyrimidines, human cytomegalovirus inhibitors 257–259
  - 2',3'-dideoxynucleoside analogues, chain terminators 9
  - dihydroquinazoliny-acetic acids, human cytomegalovirus replication inhibitors 252
  - diketo acids, HIV integrase inhibitors 4, 12
  - direct acting antiviral (DAA) drugs 319
  - DNA binding inhibitors, HIV 59–60
  - DNA binding molecules, HIV 60
  - DNA cleavage inhibition, human cytomegalovirus 248–252
  - DNA packaging inhibition, human cytomegalovirus 248–252
  - DNA polymerase inhibitors
    - aciclovir 232
    - cidovir 231
    - ganciclovir 229
    - human cytomegalovirus 238–244
    - human cytomegalovirus diseases 232
    - nucleoside analogues 238–242

- nucleotide analogues 244–245
- DNA viruses *see also* adenovirus; Epstein–Barr virus; human herpesvirus type 6; mollusciviruses; papillomavirus; parapoxviruses; polyomavirus; poxviridae
- antiviral drugs 13
- cidofovir 231
- inhibition with nucleoside phosphonates 91
- miRNAs 332
- DRB *see* 5,6-dichloro-1- $\beta$ - ribofuranosyl benzimidazole
- drug design
  - hepatitis C virus protease 310
  - oseltamivir 359–364
  - peramivir 366
  - structure-based (*see* structure-based drug design)
- drug development *see* antiviral drugs
- drug-resistant mutations
  - helicase-primase inhibitors 142
  - hepatitis C virus 158
  - herpes simplex virus 95, 135–141
  - HIV 19, 29, 41, 52, 77, 80, 151, 152
- drugs *see* antiviral drugs

**e**

- EBV *see* Epstein–Barr virus
- elvitegravir
  - chemical structure 10
  - discovery 3
  - HIV integrase inhibitor 4, 12, 55–57, 64
  - integrase strand transfer inhibitor 57
- endocytosis, HIV 33
- enfuvirtide
  - brand name and manufacturer 5
  - chemical structure 35
  - discovery 3
  - HIV treatment 11
  - inhibitors of HIV fusion 41–42
  - interaction with other drugs 152
  - protease inhibitors 41
- entecavir, chain terminators 12
- enterovirus, targeted by RNAi 333
- entry inhibition, human cytomegalovirus 235–238
- Epstein–Barr virus (EBV)
  - acyclic nucleoside phosphonates 191
  - adefovir 97
  - antiviral drugs 13
  - cidofovir 190
- error-prone replication, lethal mutagenesis 286–288

- esterification, of alkoxyalkyl compounds 182–184
- etravirine (R165335, TMC125), development 380
- eye infection 198–201
  - herpes simplex virus 1–2

**f**

- filoviridae, targeted by RNAi 333
- flaviviridae, targeted by RNAi 333
- flaviviruses *see also* hepatitis C virus
  - dengue virus 19
  - west nile virus 15
  - yellow fever 15
- flavopiridol, cyclin-dependent kinases inhibitor 262
- 1-(3-fluoro-2-phosphonylmethoxypropyl) (FPMP) analogues, acyclic nucleoside phosphonates 97–98
- FMDV *see* foot-and-mouth disease virus
- fomivirsen
  - chemical structure 230
  - human cytomegalovirus infection 229
  - mechanism of action 231
- foot-and-mouth disease virus (FMDV), ribavirin 290
- fosamprenavir, amprenavir monophosphate 78
- foscarnet (FOS)
  - chemical structure 230
  - human cytomegalovirus infection 229
  - mechanism of action 231
  - toxicity 233
- foscarnet (PFA), anti-cytomegalovirus agent 209
- Foscavir<sup>®</sup> *see* foscarnet
- FPMP *see* 1-(3-fluoro-2-phosphonylmethoxypropyl)

**g**

- ganciclovir (GCV)
  - anti-cytomegalovirus agent 209
  - chemical structure 230
  - human cytomegalovirus infection 229
  - mechanism of action 229, 232
  - resistance 232–233
  - toxicity 231, 233
- gefinitib 250
- gene expression inhibitors, human cytomegalovirus 248
- gene knockdown, RNA interference 329
- gene silencing, RNA interference 329
- generic names, antiviral drugs 5–6

- genome replication inhibitors, human
    - cytomegalovirus 238–248
  - glycoproteins, HIV *see* HIV-1 glycoproteins
  - gp41, HIV-1 glycoprotein 31–32
  - gp120
    - HIV-1 glycoprotein 30–31
    - inhibition of CD4 interaction 36
  - GPCRs *see* G-protein-coupled receptors
  - G-protein-coupled receptors (GPCRs), human
    - cytomegalovirus 256
  - graft *versus* host disease (GvHD), human
    - cytomegalovirus 228
  - GRID, neuraminidase inhibitor 355–358
  - GS4071
    - C-3 side-chain analogues 362
    - hydroxy, amino, and guanidino analogues 363
    - inhibitor-active site interactions 361–362
    - oral bioavailability 363
  - GS4104 *see also* oseltamivir
    - chemical structure 363
  - G-to-A hypermutations, HIV-1 285
  - guanosine analogues, ribavirin 289
  - GvHD *see* graft *versus* host disease
  - GW1263W94, benzimidazole ribosides *see* maribavir
  - GW275175X *see* (2-bromo-5,6-dichloro-1-( $\beta$ -D-pyranosyl)benzimidazole)
    - proposed mechanism of action 134–135
    - replication of herpes simplex virus 130–131
    - resistance of herpesviruses 135–136, 139–143
    - resistance of herpesviruses (overview) 137
    - varicella zoster virus 130–134
- h**
- HA *see* hemagglutinin
  - HAART *see* highly active antiretroviral therapy
  - Hantaan virus, ribavirin 290
  - HBB, poliovirus and other enteroviruses *see* 2-(1-hydroxybenzyl)benzimidazole
  - HBV *see* hepatitis B virus
  - HCV *see* hepatitis C virus
  - HDP-CDV *see* hexadecyloxypropyl-Cidofovir
  - HDP-cidofovir nucleotide analogue prodrug, human cytomegalovirus 241
  - helicase inhibitors, human
    - cytomegalovirus 245–246
  - helicase-primase complex
    - predicted structure 141
    - structure 130
  - helicase-primase inhibitors (HPIs)
    - cell culture and *in vivo* 133
    - cross-resistance 136–139
    - drug-resistant mutations 142
    - frequency of mutation of herpesviruses 139–140
    - helicase-primase complex 141
    - inhibition of herpesvirus DNA 131–132, 134
    - inhibition of polymerase 104–107
    - nucleoside phosphonates 2, 92, 95, 97–99, 103, 107–109, 112–115, 193, 196–197
    - nucleosides as antiviral drugs 181–182
    - phosphatidyl-ddC 183
    - protease inhibitors 3
    - replication 148
    - replication inhibition 4
    - tenofovir disoproxil fumarate 11
  - hepatitis C virus (HCV)
    - NS3-4A protease 308
    - ribavirin 288–289
    - therapy 307–316
  - hepatitis C virus genome
    - organization 308
    - translation and polypeptide processing 308
  - hepatitis C virus genotype 1
    - standard of care 307
    - sustained viral response 307
  - hepatitis C virus protease
    - catalytic triad 315
    - covalent linear, noncovalent linear, and noncovalent macrocyclic inhibitors bound to 315
    - point mutations 316–318
    - role of 308–310
  - hepatitis C virus protease inhibitors

- antiviral potency 316, 319–321
- classes 310
- clinical efficacy 319–321
- combination therapy 321
- design 310
- development 307–321
- emergence of resistance 316
- enzymatic mechanism of action 316
- future directions 321
- resistance 316–318
- roles 308
- similarities and differences 310–316
- threedimensional binding models 309–310
- hepatitis C virus protease variants 317
- N<sup>4</sup>-heptyloxycarbonyl-5,6-dihydro-5-aza-2'-deoxycytidine (KP-1461), HIV treatment 292–294
- hepsera *see* adefovir dipivoxil
- herpes simplex virus (HSV)
  - alphaherpesviruses 129
  - antiviral drugs 4–8
  - inhibitors (*see* helicase-primase inhibitors)
  - iododeoxyuridine 1
  - latent infection 134
  - resistance 135–142
- herpes simplex virus infection, prophylaxis and treatment 209
- herpesviridae
  - cytomegalovirus 209
  - herpes simplex virus 209
  - protein kinase inhibition 212
  - targeted by RNAi 333
- herpesvirus *see also* Epstein–Barr virus; herpes simplex virus; human herpesvirus type 6; varicella zoster virus
  - antiviral drugs 4–8
  - maturation 248, 256
  - replicative cycle 264
  - resistance 135–142
- 2-(hexadecyloxy)ethyl ester of cHPMP-5-azaC, human cytomegalovirus 241
- hexadecyloxypropyl adefovir, as prodrug of nucleoside phosphonates 197–198
- hexadecyloxypropyl-cidofovir (HDP-CDV)
  - anti-cytomegalovirus agent 209
  - human cytomegalovirus DNA polymerase inhibitor 244
- HHV-5 *see* human herpesvirus 5
- HHV-6 *see* human herpesvirus type 6
- highly active antiretroviral therapy (HAART)
  - combination of drugs 29
  - cytomegalovirus retinitis disease 217
  - HIV-1 integrase 55–57
  - human cytomegalovirus retinitis 227–228
  - protease inhibitors 52, 75, 87
  - treatment of HIV 52
- HIV
  - antiretroviral therapy 52 (*see also* highly active antiretroviral therapy)
  - antiviral drugs 8–12
  - integrase (*see* HIV-1 integrase)
  - lethal mutagenesis 283–297
  - mutagenic 5-Hydroxy-2'-deoxycytidine 290–291
  - mutation rates 285
  - nonsynonymous mutations 286
  - replication cycle 51–52
- HIV-1
  - allosteric site for binding NNRTIs 379
  - cytomegalovirus retinitis disease treatment 214–217
  - G-to-A hypermutations 285
  - lethal mutagenesis 286–288
  - mutagenic 5-Azacytidine 291–292
  - mutagenic 5-Hydroxy-2'-deoxycytidine 291
  - mutagenic deoxyribonucleosides 286–287
  - mutagenic ribonucleosides 286–288
  - mutation rates 285–286
  - RNAi gene therapy 338–339
- HIV DNA binding, inhibition 59–60
- HIV entry
  - inhibition 34–42
  - mechanism 32–33
- HIV fusion, inhibitors 41–42
- HIV-1 glycoproteins
  - structure of gp120 30–31
  - structure of transmembrane gp41 31–32
- HIV IN *see* HIV-1 integrase
- HIV inhibition
  - cyclophilin 151–155
  - DNA binding 59–60
  - integrase (*see* HIV integrase inhibitors)
  - multimerization 60–62
- HIV integrase
  - catalysis 53
  - inhibition (*see* HIV integrase inhibitors)
- HIV-1 integrase (HIV IN)
  - as a target for HAART 55–57
  - cofactor interactions 62–64
  - enzymatic mechanism of the integration reaction 53
  - mechanism of integration 53–54
  - strand transfer reaction 12
  - structural organization 54–55
- HIV integrase inhibitors
  - diketo acid group 4, 12
  - elvitegravir (*see* elvitegravir)
  - first (*see* raltegravir)

- integrase binding 57–59
- integrase cofactor interactions 62–64
- integration step 53–59
- raltegravir 41 (*see also* raltegravir)
- strand transfer 55–57
- HIV integration reaction, enzymatic
  - mechanism 53–59 *see also* HIV integrase inhibitors
- HIV multimerization, inhibition 60–62
- HIV-1 replication, inhibitor 378
- HIV-1 reverse transcriptase
  - fidelity 285
  - mutation rate increasing 286–287
  - role in the replication cycle 379
  - TIBO binding site 378
- HIV protease, as target for AIDS 73–74
- HIV treatment, *N*<sup>4</sup>-heptyloxycarbonyl-5,6-dihydro-5-aza-2'-deoxycytidine 292–294
- HIV treatment drug classes
  - chemokine receptor antagonist 73
  - entry and fusion inhibitor (*see* HIV entry)
  - integrase inhibitors (*see* HIV integrase inhibitors)
  - nonnucleoside reverse transcriptase inhibitors (*see* reverse transcriptase)
  - nucleoside/nucleotide reverse transcriptase inhibitors (*see* nucleoside phosphonates)
  - overview 29, 73
  - protease inhibitors (*see* protease inhibitors)
- host kinases, nucleoside phosphonates 92–94
- host mechanisms, as target for antiviral drugs 147
- HPIs *see* helicase-primase inhibitors
- HPMP *see* (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)
- HPMP-5-azaC *see* (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-5-aza-cytosine
- HPMPA *see* (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)-adenine
- HPMPC *see* (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
- HSCT *see* hematopoietic stem cell transplant
- HSV *see* herpes simplex virus
- HTLV-III/LAV 377 *see also* HIV-1
- human cytomegalovirus (HCMV) *see also* cytomegalovirus
  - antiviral drugs 229–234
  - cellular targets inhibitors 260–265
  - chemokine receptors agonist 256–258
  - cyclin-dependent kinases inhibitors 261–262
  - cyclooxygenase 2 inhibitors 262–263
  - diseases 227–229
  - DNA polymerase 246
  - DNA polymerase inhibitors 238–245
  - DNA replication 247–248
  - gene expression inhibitors 248
  - infection prophylaxis after transplantation 228–229
  - infections (*see* specific infections)
  - inhibitors of viral genome replication 238–248
  - inhibitors of virion assembly and egress 248–256
  - inhibitors with a mechanism of action not fully unraveled 258–260
  - manifestation of infection 227–228
  - new inhibitors 256–258
  - novel drug targets and strategies 264
  - novel viral targets 235–260
  - protease inhibitors 250, 256
  - proteasome inhibitors 263–265
  - protein kinase pUL97 229–230, 253
  - replication inhibition 238–248
  - viral entry inhibitors 235–238
  - viral genome replication inhibitors 238–248
  - virion assembly and egress 248–256
- human cytomegalovirus retinitis 227–228
  - see also* cytomegalovirus retinitis
  - cidofovir 231
  - fomivirsen 231
- human herpesvirus 5 (HHV-5) *see* cytomegalovirus; human cytomegalovirus
- human herpesvirus type 6 (HHV-6)
  - acyclic nucleoside analogue 238–240
  - antiviral drugs 13
  - human cytomegalovirus inhibitors 258
  - nonnucleoside Analogues 243
  - nucleotide Analogues 244
  - phosphorothioated oligonucleotides 237
- human immunodeficiency virus *see* HIV; retroviruses
- 2-(1-hydroxybenzyl)benzimidazole (HBB) 1
- 5-hydroxy-2'-deoxycytidine (5-OH-dC), mutagenic HIV pharmaceutical 290–291
- hydroxyethylene scaffold, protease inhibitors 11
- (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)-adenine (HPMPA), acyclic nucleoside phosphonates 95
- (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) (HPMP), acyclic nucleoside phosphonates 95
- (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-5-aza-cytosine



(HPMP-5-azaC), human cytomegalovirus DNA polymerase inhibitor 241, 245  
 (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) *see also* cidofovir  
 – human cytomegalovirus DNA polymerase inhibitor 245  
 hypermutations, G-to-A 285

**i**

IDU *see* iododeoxyuridine  
 imidazolylpyrimidines, human  
 cytomegalovirus helicase/primase complex inhibitor 245–246  
 imidoylthiourea (ITU)  
 – analogues 381  
 – chemical structure 380  
 immunocompromised patients,  
 cytomegalovirus diseases 227  
 immunosuppression, cyclosporin A 147  
 IMPDH *see* inosine 5'-monophosphate dehydrogenase  
 INBI *see* integrase binding inhibitors  
 indolocarbazoles, human cytomegalovirus protein kinase inhibitors 250, 255  
 influenza, pandemics 351  
 influenza A infection 14–15  
 influenza neuraminidase, as a drug target 353–354  
 influenza neuraminidase inhibitors,  
 resistance 368–369  
 influenza strain H1N1, neuraminidase inhibitors treatment 368–370  
 influenza strain H5N1, oseltamivir treatment 368  
 influenza vaccines 352  
 influenza virus  
 – antiviral drugs 14–15  
 – parainfluenza 106  
 – research interest 143  
 – types and subtypes 351–352  
 – zanamivir 198  
 influenza virus multiplication, 5,6-dichloro-1- $\beta$ -D-ribofuranosyl benzimidazole 1  
 inhaled neuraminidase inhibitors 358–359  
 inosine 5'-monophosphate dehydrogenase (IMPDH), inhibition 288–289  
 INSTI *see* integrase strand transfer inhibitors  
 integrase binding inhibitors, HIV 57–59  
 integrase cofactor interactions, HIV 62–64  
 integrase inhibitors, HIV *see* HIV integrase inhibitors  
 integrase strand transfer inhibitors (INSTI), HIV 55–57 *see also* HIV-1 Integrase; HIV integrase inhibitors

interferon cytokines, cyclophilins 155, 161, 173  
 intracellular metabolic pathways, nucleoside phosphonates 93  
 intraocular delivery, of antiviral prodrugs 198–201  
 intrinsic mutagenesis  
 – retroviruses 284–286  
 – RNA viruses 284–286  
 iododeoxyuridine (IDU)  
 – alphaherpesviruses 129  
 – discovery 3  
 – first antiviral drug 1  
 – herpes simplex virus 1–2  
 (2-isopropylamino-5,6-dichloro-1( $\beta$ -D-ribofuranosyl)benzimidazole (1263W94) *see also* maribavir  
 – cytomegalovirus inhibitor 210  
 ITU *see* imidoylthiourea

**k**

KP-1212 *see* 5-aza-5,6-dihydro-2'-deoxycytidine  
 KP-1461 *see* N<sup>4</sup>-heptyloxycarbonyl-5,6-dihydro-5-aza-2'-deoxycytidine

**l**

laninamivir (CS-8958) 358–359  
 latency, of infection 134, 227  
 LBV *see* lobucavir  
 leflunomide *see also* N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide  
 – human cytomegalovirus inhibitors 259–260  
 lethal mutagenesis  
 – challenges and advantages 294–296  
 – fundamentals 286–288  
 – future perspectives 296–297  
 – HIV 283–297  
 – vs. conventional strategies (HIV) 294–296  
 lethal mutagens  
 – deoxyribose nucleosides 287  
 – ribavirin 288–290  
 – ribonucleoside analogues 287  
 linear and macrocyclic HCV protease inhibitors, cross-resistance 318  
 lobucavir (LBV)  
 – human cytomegalovirus DNA polymerase inhibitor 238  
 – structure 239  
 lopinavir  
 – brand name and manufacturer 5  
 – chemical structure 76  
 – combination with ritonavir 77–78

- comparison to darunavir 86
- discovery 3
- HIV protease inhibitor 80
- loviride (R89439) 380–381

**m**

- mammalian viruses, RNAi mechanism 331–332
- maraviroc, HIV treatment 38
- maribavir *see also* benzimidazole ribosides
  - antiviral activity 210–212
  - blood-brain barrier crossing 217
  - clearance in animal species 215
  - clinical development 215–217
  - clinical phase I and II studies in treatment of cytomegalovirus retinitis disease 214–217
  - clinical phase II study in prophylaxis of cytomegalovirus disease in transplant recipients 218
  - clinical phase III study with stem cell transplant recipients 218
  - clinical studies phases I-III 254–255
  - cytotoxicity in animal species 215
  - failure of study with allogeneic stem cell transplant recipients 220
  - interactions with tacrolimus 219
  - mechanism of action 212–214, 252–253
  - metabolism 214, 218–219
  - oral bioavailability in animal studies 214
  - pivotal study in liver transplant recipients 218–220
  - preclinical studies 214–215
  - prevention and treatment of cytomegalovirus diseases 209–221
  - prophylaxis of cytomegalovirus diseases 218–221
  - renal transplant recipients 219
  - resistance 212–214, 220
  - role of P450 enzymes 218–219
  - selectivity 213
  - structure 210–211
  - toxicology in animal studies 214
  - transplant population 218–220
  - treatment of cytomegalovirus diseases 215–217
  - UL97 protein kinase (pUL97) inhibitor 252–255
  - viral protein kinase inhibition 212–213
- maribavir pharmacokinetics
  - cytomegalovirus retinitis disease 216
  - effect of hepatic impairment 218–219
  - effect of renal impairment 219
- mechanistic classes of HIV treatment drugs

- chemokine receptor antagonist 73
- entry and fusion inhibitor (*see* HIV entry)
- integrase inhibitors (*see* HIV integrase inhibitors)
- nonnucleoside reverse transcriptase inhibitors (*see* reverse transcriptase)
- nucleoside/nucleotide reverse transcriptase inhibitors (*see* nucleoside phosphonates)
- overview 29, 73
- protease inhibitors (*see* protease inhibitors)
- metabolic pathways, nucleoside phosphonates 93
- microRNA (miRNA), pathway 330–331
- mollusciviruses
  - anti human cytomegalovirus 231
  - antiviral drugs 13
  - cidofovir 112
- monkeypox
  - acyclic nucleoside phosphonates 99, 190
  - antiviral drugs 17–18
- Muller's ratchet 297
- multimerization inhibitors, HIV 60–62
- mutagenesis, lethal 286–288 *see also* lethal mutagenesis
- mutagenic deoxyribonucleosides, HIV-1 286–287
- mutagenic pharmaceuticals
  - 5-azacytidine 291–292
  - 5-Hydroxy-2'-deoxycytidine 290–291
  - antiviral agents 288–292
  - ribavirin 288–290
- mutagenic ribonucleosides, HIV-1 incorporation 286–288
- mutation rates
  - HIV 285–286
  - RNA viruses 284
- mutations
  - nonsynonymous 286
  - viruses (*see* drug-resistant mutations)

**n**

- NA *see* neuraminidase
- narlaprevir, binding to NS3 protease variants 316–318
- Neu5Ac2en (DANA) *see* 2-deoxy-2,3-didehydro-N-acetylneuraminic acid
- neuraminidase (NA) *see also* influenza neuraminidase
  - active site 354–355
  - aromatic inhibitors 364–365
  - crystal structure 354–355
  - cyclopentane-based inhibitors 364
  - influenza A viruses 351–352
  - inhibitor binding 354–355

- oseltamivir-based inhibitors 364–365
  - small-molecule inhibitors 355–364
  - zanamivir-based inhibitors 364–365
  - neuraminidase active site, crystal structure 354–355
  - neuraminidase inhibitors 369
    - ABT-675 366–367
    - anti-influenza agents 351–370
    - based on other scaffolds 364–367
    - clinical use 367–369
    - influenza 352–353
    - inhaled (*see* inhaled neuraminidase inhibitors)
    - laninamivir 358–359
    - oseltamivir 359–364
    - peramivir 364–366
    - resistance 364
    - zanamivir 355–358
  - nitropyrimidines, human cytomegalovirus helicase/primase complex inhibitor 245–246
  - NNRTIs *see* nonnucleoside reverse transcriptase inhibitors
  - noncovalent linear hepatitis C virus protease inhibitors
    - chemical structures 312
    - enzyme-inhibitor interaction kinetics 312
    - log octanol/water partition coefficient 312
    - molecular weights 312
    - pattern of resistance 318
    - polar surface area 312
  - noncovalent macrocyclic hepatitis C virus protease inhibitors
    - chemical structures 313–314
    - enzyme-inhibitor interaction kinetics 313–314
    - log octanol/water partition coefficient 313–314
    - molecular weights 313–314
    - pattern of resistance and cross-resistance 318
    - polar surface area 313–314
  - noncovalent protease inhibitors, resistance 318
  - noncyclosporine cyclophilin inhibitors, antiviral drugs 168–173
  - nonnucleoside analogues, human cytomegalovirus DNA polymerase inhibitor 240, 242–243
  - nonnucleoside antivirals 230
  - nonnucleoside inhibitors, phenylenediamine sulphonamides 248–251
  - nonnucleoside reverse transcriptase inhibitors (NNRTIs), HIV-1 377–379
  - NS3 protease 309–310
  - NS3 protease inhibitors, resistance and cross-resistance 316–318
  - NS3 protease variants, sensitivity to inhibitors 316–318
  - NS3-4A protease/helicase complex, threedimensional model 309–310
  - NS3-4A protease, hepatitis C virus 308–310
  - nucleoside 5'-monophosphates, prodrugs 185–189
  - nucleoside analogues
    - anti-cytomegalovirus drugs 209
    - anti-HIV drug resistance 295–296
    - antiviral activity 295
    - ganciclovir 230
    - human cytomegalovirus DNA polymerase inhibitor 238–243
    - incorporation into HIV-1 genome 294
    - mutagenic effects 288
  - nucleoside phosphonates
    - antiviral drugs (*see* acyclic nucleoside phosphonates; cyclic nucleoside phosphonates)
    - clinical applications 111–115
    - examples 92
    - metabolic pathways 93
    - oral bioavailability 107–111
    - prodrugs 107–111 (*see also* alkoxyalkyl ester prodrugs)
    - strategy for antiviral drugs 92–95
  - nucleotide analogues
    - cidovir 230
    - human cytomegalovirus DNA polymerase inhibitor 241, 244–245
- o**
- 5-OH-dC *see* 5-hydroxy-2'-deoxycytidine
  - oligodeoxyribonucleotides (ODNs), phosphorothioate-modified 237
  - olomoucine, cyclin-dependent kinases inhibitor 262
  - orf viruses
    - acyclic nucleoside phosphonates 191, 195
    - anti human cytomegalovirus 231
    - antiviral drugs 13
  - orthomyxoviridae, targeted by RNAi 333
  - orthomyxoviruses *see* influenza virus
  - orthopoxviruses *see also* smallpox
    - studies of smallpox antivirals 191
  - oseltamivir
    - avian influenza strain H5N1 368
    - chemical structure 353
    - clinical use 367–368

- influenza treatment and prevention 352–353
  - inhibitor design 359–364
  - resistance 364, 368–369
  - oseltamivir (GS4104) 359–364
  - mechanism of resistance 364
  - 4-oxo-1,4-dihydroquinoline (DHQ)
    - carboxamides, human cytomegalovirus DNA polymerase inhibitor 240, 242
  - 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides, human cytomegalovirus DNA polymerase inhibitor 240, 243
  - 7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides, human cytomegalovirus DNA polymerase inhibitor 240, 243
- P**
- papillomavirus
    - acyclic nucleoside phosphonates 95–97
    - antiviral drugs 13
    - cidofovir 112
    - cyclosporin A and derivatives 167
    - phosphonoamidates 110
  - papovaviridae, targeted by RNAi 333
  - parainfluenza, cyclic nucleoside phosphonates 106
  - paramyxoviridae, targeted by RNAi 333
  - parapoxviruses *see also* orf viruses
    - antiviral drugs 13
  - peptide aptamer technology 246–247
  - $\beta$ -peptides 236
  - human cytomegalovirus entry inhibitor 235
  - peptides, generation of cyclophilin inhibitors 168–169
  - peptidyl-prolylisomerase, cyclophilins 168
  - peramivir (BCX-1812, RWJ-270201) 364–366
    - inhibitor design 366
  - peramivir, chemical structure 366
  - PFA *see* phosphonoformic acid
  - pharmacophores
    - antiviral drugs 7–8, 19
    - cyclophilin inhibitors 171
    - hepatitis C virus 15
    - in antiretrovirus agents (overview) 9
    - model 57
    - optimization and design of inhibitors 56–60
  - phenylenediamine sulphonamides (BAY 38-4766), human cytomegalovirus replication inhibitors 248–251
  - phosphonates, antiviral drugs *see* acyclic nucleoside phosphonates; cyclic nucleoside phosphonates; nucleoside phosphonates
  - phosphonoamidates, as prodrugs of nucleoside phosphonates 107–111
  - phosphonoesters, as prodrugs of nucleoside phosphonates 107–109
  - phosphonoformic acid (PFA) 185 *see also* foscarnet
  - 9-(2-phosphonylmethoxyethyl)adenine (PMEA), acyclic nucleoside phosphonates 95–97
  - 9-(2-phosphonylmethoxypropyl) (PMP) analogues, acyclic nucleoside phosphonates 97–98
  - phosphorothioate-modified oligonucleotides, human cytomegalovirus entry inhibitor 237–238
  - picornaviridae, targeted by RNAi 333
  - PIs *see* protease inhibitors
  - plaque reduction assays 132–133
    - helicase-primase inhibitors 132–133, 141
  - PMEA *see* 9-(2-phosphonylmethoxyethyl)adenine
  - PMP *see* 9-(2-phosphonylmethoxypropyl)
  - point mutations, resistance to protease inhibitors 316–318
  - poliovirus, infection 1
  - polyanions, as inhibitors of HIV attachment 34–36
  - polymerase, hepatitis C virus 104–107
  - polyomavirus
    - acyclic nucleoside phosphonates 96
    - antiviral drugs 13
  - portal proteins 252
  - postattachment inhibitors, HIV entry 37
  - posttranscriptional gene silencing (PTGS) 329
    - mammals 331
  - poxviridae *see also* poxviruses; vaccinia virus; variola virus
    - antiviral drugs 13
  - poxviruses *see also* variola virus
    - acyclic nucleoside phosphonates 194
    - antiviral drugs 17–18
    - antiviral effects of cidofovir derivatives 190
    - cidofovir derivatives 189–190
  - primase inhibitors, human cytomegalovirus 245–246
  - pro-140, HIV treatment 39
  - prodrugs
    - of nucleoside phosphates (*see* alkoxyalkyl (ester) prodrugs)

- of nucleoside phosphonates (*see* alkoxyalkyl (ester) prodrugs)
  - of phosphonofornate (*see* alkoxyalkyl (ester) prodrugs)
  - oral 189–198
  - protease
    - HIV 73–74
    - viral target for HIV therapy 29–30
  - protease inhibitors (PIs)
    - amprenavir (*see* amprenavir)
    - darunavir (*see* darunavir)
    - early developments 74–78
    - first 2, 75 (*see also* saquinavir)
    - hepatitis C virus 3
    - highly active antiretroviral therapy 52, 75, 87
    - HIV 73–74
    - human cytomegalovirus 250, 256
    - hydroxyethylene scaffold 11
    - lopinavir (*see* lopinavir)
    - medical need for next generation 78–85
    - ritonavir (*see* ritonavir)
    - safety profile 321
    - saquinavir (*see* saquinavir)
    - tipranavir (*see* tipranavir)
  - proteasome inhibitors, human
    - cytomegalovirus 262–265
  - protein kinase family, herpesviridae 212
  - protein kinase inhibitor, maribavir 212
  - protein-protein interactions inhibition, human
    - cytomegalovirus 246–248
  - prusoff, iododeoxyuridine 1
  - PTGS *see* posttranscriptional gene silencing
  - pUL84, human cytomegalovirus replication factor 247–248
  - pUL97
    - cytomegalovirus protein kinase 211
    - human cytomegalovirus protein kinase 253
  - purine cyclic nucleoside phosphonates, chemical structures 102
  - pyrimidine cyclic nucleoside phosphonates, chemical structures 100
  - pyrophosphate analogue, foscarnet 230
  - pyrrolidine-5,5-trans-lactams 250
- q**
- quinazolines, human cytomegalovirus protein kinase inhibitors 250, 255
  - quinoxaline derivatives, design starting from cyclophilins structures 169–170
- r**
- R89439 *see* lorigide
  - R147681 *see* dapivirine
  - R165335 *see* etravirine
  - R278474 *see* rilpivirine
  - R-125489 358–359
  - raltegravir
    - brand name and manufacturer 6
    - chemical structure 10
    - discovery 3
    - first HIV integrase inhibitor 4, 12, 72
    - HIV integrase inhibitor 41, 55–57, 64
    - integrase strand transfer inhibitor 57
  - RBV *see* ribavirin
  - Relenza® *see* zanamivir
  - reoviridae, targeted by RNAi 333
  - replicative cycle, herpesviruses 264
  - respiratory syncytial virus (RSV), RNAi therapy 337
  - retroviridae, targeted by RNAi 333
  - retroviruses *see also* HIV
    - acyclic nucleoside phosphonates 96–99, 196–197
    - antiviral drugs 8–12
    - inhibition with nucleoside phosphonates 91
    - intrinsic mutagenesis 284–286
    - viral fitness 284–286
  - reverse transcriptase (RT)
    - HIV-1 378
    - viral target for HIV therapy 29–30
  - rhabdoviridae, targeted by RNAi 333
  - ribavirin (RBV)
    - antiviral activity 2
    - brand name and manufacturer 6
    - chemical structure 7, 106
    - chronic HCV genotype 1 162–165
    - discovery 3
    - hepatitis C 155–157, 173
    - hepatitis C and cyclophilin 15
    - influenza A 14
    - mechanism of action 8, 289
    - mutagenic pharmaceutical 288–290
    - RNA virus 104
  - 1- $\beta$ -D-ribofuranosyl-1,2,4-triazole-3-carboxamide *see* ribavirin
  - 1-( $\beta$ -L-ribofuranosyl)-2-isopropylamino-5,6-dichlorobenzimidazole (GW1263W94) *see* maribavir
  - ribonucleoside analogues
    - 5-Azacytidine 291–292
    - 5-Hydroxy-2'-deoxycytidine 290–291
    - lethal mutagens 287
    - ribavirin 288–290
  - rilpivirine 377–385
    - clinical proof of concept 383–384
    - combination therapy 385

- development 380
  - drug-drug interactions 383–384
  - mechanism of action 381–383
  - pharmacokinetics 383–384
  - potency 384–385
  - resilience to NNRTI resistance 384–385
  - resistance 385
  - rilpivirine (R278474, TMC278) 380–381
    - structure-activity relationship 381–383
  - rimantadine, influenza treatment 352–353
  - RISC *see* RNA-induced silencing complex
  - ritonavir
    - body absorption 75
    - brand name and manufacturer 5
    - chemical structure 76
    - combination with elvitegravir 56
    - combination with lopinavir 77–78
    - comparison to darunavir 86
    - discovery 3
    - HIV protease inhibitor 80
  - RNAi *see also* RNA interference
    - antiviral activity 331–332
    - selecting optimal targets 332–334
  - RNAi gene knockdown, high-throughput screens 334
  - RNAi gene therapy
    - chronic infection 337–338
    - future perspective 338–339
    - HIV-1 infection 337–338
  - RNAi mechanism
    - mammalian viruses 331–332
    - therapeutic application 329–331
  - RNA-induced silencing complex (RISC) 331
  - RNA interference (RNAi) 248
    - see also* RNAi
    - discovery 329
  - RNAi strategies, prevention of viral escape 334–335
  - RNAi therapy
    - basic design 332
    - potential risks 336–337
  - RNA viruses
    - hepatitis C virus 92, 155
    - intrinsic mutagenesis 284–286
    - mutagenic nucleoside analogues 288
    - mutation rates 284
    - replication inhibitor 288–289
    - viral fitness 284–286
  - roscovitine, cyclin-dependent kinases inhibitor 262
  - RSV *see* respiratory syncytial virus
  - RT *see* reverse transcriptase
  - RWJ-270201 *see* peramivir
- S**
- S2242 *see* 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine
  - saquinavir
    - brand name and manufacturer 5
    - chemical structure 10, 76
    - discovery 3
    - first HIV protease inhibitor 2
    - HIV protease inhibitor 80, 82
    - HIV treatment 75, 80
    - hydroxyethylene scaffold 11
  - SAR *see* structure-activity relationship
  - second-generation HIV integrase inhibitors
    - see* HIV integrase inhibitors
  - Selzentry® *see* maraviroc
  - sequence-specific gene silencing 329
  - sialic acid analogues, neuraminidase inhibitor 355–358
  - sialidase, neuraminidase 352
  - siRNAs
    - delivery issues 335–336
    - multiplexing 335–336
  - siRNA treatment, escape for several viruses 334
  - small interfering RNAs, human cytomegalovirus 248
  - small-molecule inhibitors, HIV entry 36–37
  - smallpox *see also* biological weapon; poxviruses; variola virus
    - orthopoxviruses 191
    - vaccine 1, 17, 189
  - SOC *see* standard of care
  - solid organ transplant (SOT), human cytomegalovirus infection 228
  - spontaneous mutations, HIV 286
  - standard of care (SOC), hepatitis C virus genotype 1 307
  - strand transfer inhibitors *see* integrase strand transfer inhibitors
  - strand transfer reaction, HIV integrase 12
  - structure-activity relationship (SAR) 242
    - acyclic nucleoside phosphonates 95–98
    - cyclic nucleoside phosphonates 100–104
  - rilpivirine//HIV-1 reverse transcriptase 381–383
  - structure-based drug design
    - hepatitis C virus protease inhibitors 234–238
    - influenza neuraminidase inhibitors 369
    - zanamivir 355–358
  - surface protein, viral 30
  - sustained viral response (SVR), hepatitis C virus therapy 307
  - SVR *see* sustained viral response

**t**

- Tamiflu® *see* oseltamivir  
 TCRB *see* (2,5,6-trichloro-1-( $\beta$ -D-ribofuranosyl) benzimidazole  
 TDF *see* tenofovir disoproxil fumarate  
 telaprevir  
 – binding to NS3 protease variants 316–318  
 – phase 2 clinical trials 319–320  
 tenofovir  
 – acyclic nucleoside phosphonates 97–98  
 – alkoxyalkyl esters 196–197  
 tenofovir disoproxil fumarate (TDF) *see also*  
 acyclic nucleoside phosphonates  
 – clinical application of nucleoside phosphonate 113–115  
 – hepatitis B virus and HIV 11, 92, 97–99, 196  
 tetrahydrofuran core phosphonates  
 – cyclic nucleoside phosphonates 100–103  
 – purine cyclic nucleoside phosphonates 102  
 – pyrimidine cyclic nucleoside phosphonates 100  
 tetrahydro-imidazo[4,5,1-*jk*][1,4]-benzodiazepin-2(1H)-one (TIBO) 378  
 4'-thiopyrimidine nucleosides 242  
 – human cytomegalovirus infection 242  
 thiourea derivatives, entry inhibitor 236–237  
 thymidine analogue, iododeoxyuridine 1  
 TIBO *see also* tetrahydro-imidazo[4,5,1-*jk*][1,4]-benzodiazepin-2(1H)-one  
 – chronicle of the discovery 377–385  
 – derivatives 378–379  
 TIBO R82150 378  
 TIBO R82913 378  
 TIBO R86183 378  
 tipranavir  
 – brand name and manufacturer 5  
 – chemical structure 76  
 – development 78–79  
 – discovery 3  
 – enfuvirtide 41  
 – HIV protease inhibitor 80  
 – no hydroxyethylene scaffold 11  
 tivirapine, chemical structure 378  
 TMC120 *see* dapivirine  
 TMC125 *see* etravirine  
 TMC278 *see* rilpivirine  
 transmembrane glycoprotein, HIV *see* HIV-1 glycoproteins  
 transplant recipients  
 – cytomegalovirus disease prophylaxis 218–220  
 – human cytomegalovirus infection and diseases 228

- (2,5,6-trichloro-1-( $\beta$ -D-ribofuranosyl) benzimidazole (TCRB), cytomegalovirus inhibitor 210, 251  
 N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide, human cytomegalovirus inhibitors 259

**u**

- UL97 protein kinase (pUL97) inhibitors, human cytomegalovirus 250, 252–255  
 UL54-UL44 interaction, human cytomegalovirus 246

**v**

- vaccines  
 – poliovirus 1  
 – smallpox 1, 17, 189  
 vaccinia virus  
 – acyclic nucleoside phosphonates 191–194  
 – antiviral drugs 17–18  
 – antiviral effects of cidofovir derivatives 190  
 – cyclosporin A and derivatives 167  
 – nucleoside phosphates and phosphonates 190  
 – thiosemicarbazones 1  
 valacyclovir (VACV), human cytomegalovirus 229  
 Valcyte® *see* valganciclovir  
 valganciclovir (VGCV), human cytomegalovirus disease prophylaxis 229–230  
 varicella zoster virus (VZV)  
 – alphaherpesviruses 129  
 – antiviral drugs 4–8, 104, 146, 191, 197  
 – helicase-primase inhibitors 130–134  
 – mutation 136, 181  
 variola virus (VARV) *see also* poxviruses; smallpox  
 – acyclic nucleoside phosphonates 189–190  
 – antiviral drugs 17–18  
 VDA *see* viral decay acceleration  
 VGCV *see* valganciclovir  
 vicriviroc, HIV treatment 39  
 Vidaza® *see* 5-azacytidine  
 viral decay acceleration (VDA) 292  
 viral fitness  
 – retroviruses 284–286  
 – RNA viruses 284–286  
 viral surface protein, HIV entry 30  
 viral targets, earlier HIV therapy 29–30  
 Virazole® *see* ribavirin  
 viread *see* tenofovir disoproxil fumarate

- virion assembly and egress inhibition, human cytomegalovirus 248–256
  - virus attachment, inhibitors 34–37
  - virus-cell fusion, HIV entry 33
  - virus entry, HIV *see* HIV entry
  - virus silencing, antiviral RNAi 329–339
  - virus tropism and infectivity, coreceptors 33
  - viruses
    - enteroviruses 1
    - hepatitis B (*see* hepatitis B virus)
    - hepatitis C (*see* hepatitis C virus)
    - herpes 4–8
    - herpes simplex 1
    - influenza 1
    - polio 1
    - smallpox 1
    - varicella zoster 4–8
  - Vistide® *see* cidofovir
  - Vitravene® *see* formivirsen
  - VZV *see* varicella zoster virus
- W**
- 1263W94 *see* (2-isopropylamino-5,6-dichloro-1(β-D-ribofuranosyl)benzimidazole (1263W94)
  - west nile virus
    - nucleosides 15
    - ribavirin 290
- X**
- X-ray crystallography
    - GS4071/neuraminidase complex 361, 369
    - hepatitis C virus protease inhibitors 315, 318
    - human cytomegalovirus protease inhibitors 256
    - neuraminidase inhibitor 355–358
    - peramivir/neuraminidase complex 369
    - pyrrolidine- and cyclopentane-based neuraminidase inhibitors 367
    - zanamivir/neuraminidase complex 361, 369
  - X-ray diffraction
    - NNRTI binding pocket within the HIV-1 reverse transcriptase 381
    - rilpivirine/HIV-1 reverse transcriptase complex 381
- Y**
- yellow fever, nucleosides 15
- Z**
- zanamivir
    - C-6 carboxamide analogues 356–357
    - C-6 carboxamide, ether, ketone, and hydroxy analogues 357
    - chemical structure 353
    - clinical use 367–368
    - derivatives 198
    - dimeric analogues 358
    - glycerol side-chain analogues 358–359
    - heterocyclic analogues 357–358
    - influenza treatment and prevention 352–353
    - inhibitor activity 356
    - inhibitor design 355–358
    - neuraminidase inhibitor 355–358
    - resistance 368–369
  - zidovudine *see also* AZT
    - brand name and manufacturer 5